Seres Therapeutics to Participate in Piper Sandler Healthcare Conference

Company Overview - Seres Therapeutics, Inc. is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics [3] - The company successfully developed and approved VOWST™, the first FDA-approved orally administered microbiome therapeutic, which was sold to Nestlé Health Science in September 2024 [3] - Seres is developing SER-155, which has shown a significant reduction in bloodstream infections and related complications in a clinical study involving patients undergoing allogeneic hematopoietic stem cell transplantation [3] Pipeline and Development - SER-155 and other pipeline programs are designed to target multiple disease-relevant pathways and are manufactured from standard clonal cell banks via cultivation [3] - The company plans to evaluate SER-155 and other cultivated live biotherapeutic candidates in various medically vulnerable patient populations, including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, and patients in intensive care units and long-term acute care facilities [3] Upcoming Events - Eric Shaff, President and CEO of Seres Therapeutics, will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024, at 4:30 p.m. ET [1] - A live webcast of the chat will be available on the company's website and will be accessible for replay after the event [2]